Bromhexine is a potential drug for COVID-19; From hypothesis to clinical trials

Bromhexine is a potential drug for COVID-19; From hypothesis to clinical trials

COVID-19 (novel coronavirus disease 2019), caused by the SARS-CoV-2 virus, has various clinical manifestations and several pathogenic pathways. Although several therapeutic options have been used to control COVID-19, none of these medications have been proven to be a definitive cure. Transmembrane s...

Full description

Bibliographic Details
Main Authors:	S. Bahadoram, B. Keikhaei, M. Bahadoram, M.-R. Mahmoudian-Sani, S. Hassanzadeh, A. Saeedi-Boroujeni, K. Alikhani
Format:	Article
Language:	English
Published:	Central Research Institute for Epidemiology 2022-05-01
Series:	Вопросы вирусологии
Subjects:	sars-cov-2 covid-19 bromhexine tmprss2 covid-19 prevention covid-19 treatment
Online Access:	https://virusjour.crie.ru/jour/article/viewFile/608/379

Similar Items

Blocking serine protease (TMPRSS2) by Bromhexine; looking at potential treatment to prevent COVID-19 infection
by: Ramin Tolouian, et al.
Published: (2020-07-01)

Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial
by: María Luz Vila Méndez, et al.
Published: (2022-12-01)

Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trialResearch in context
by: Dhammika Leshan Wannigama, et al.
Published: (2024-04-01)

Publication trend of TMPRSS2 as SARS-CoV-2 receptor during the COVID-19 pandemic
by: Lalu Muhammad Irham, et al.
Published: (2023-03-01)

Expression Pattern of the SARS-CoV-2 Entry Genes <i>ACE2</i> and <i>TMPRSS2</i> in the Respiratory Tract
by: Yichuan Liu, et al.
Published: (2020-10-01)

Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients
by: Laksmi Wulandari, et al.
Published: (2021-05-01)

ACE2 and TMPRSS2 Immunolocalization and COVID-19-Related Thyroid Disorder
by: Gi-Cheol Park, et al.
Published: (2022-04-01)

ACE-2, TMPRSS2 and Beyond; Promising Targets and Tools for COVID-19 Prophylaxis and Treatment
by: Akçahan GEPDİREMEN, et al.
Published: (2020-12-01)

Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment
by: Xiaoqiang Huang, et al.
Published: (2021-06-01)

The fatal contribution of serine protease-related genetic variants to COVID-19 outcomes
by: Laura Edith Martínez-Gómez, et al.
Published: (2024-03-01)

TMPRSS2 gene polymorphism common in East Asians confers decreased COVID-19 susceptibility
by: Takeshi Sekiya, et al.
Published: (2022-11-01)

A Plausible Link of TMPRSS2/ACE2/AR Signaling to Male Mortality during the COVID-19 Pandemic in the United States
by: Lilly M. Wong, et al.
Published: (2021-10-01)

Smoking-Mediated Upregulation of the Androgen Pathway Leads to Increased SARS-CoV-2 Susceptibility
by: Jaideep Chakladar, et al.
Published: (2020-05-01)

Bioinformatics Analysis of Allele Frequencies and Expression Patterns of ACE2, TMPRSS2 and FURIN in Different Populations and Susceptibility to SARS-CoV-2
by: Mohammad Tarek, et al.
Published: (2021-07-01)

Electrodeposition of Cobalt Oxides on Carbon Nanotubes for Sensitive Bromhexine Sensing
by: Sireerat Lisnund, et al.
Published: (2022-06-01)

Structural Variability, Expression Profile, and Pharmacogenetic Properties of TMPRSS2 Gene as a Potential Target for COVID-19 Therapy
by: Aleksei Zarubin, et al.
Published: (2020-12-01)

Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview
by: Anna Gorący, et al.
Published: (2022-05-01)

Novel approach by natural language processing for COVID-19 knowledge discovery
by: Li Wang, et al.
Published: (2022-06-01)

Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming
by: Elisa Barile, et al.
Published: (2020-05-01)

<i>In Silico</i> Molecular Characterization of Human TMPRSS2 Protease Polymorphic Variants and Associated SARS-CoV-2 Susceptibility
by: Mohd Zulkifli Salleh, et al.
Published: (2022-02-01)

Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity
by: Mohamed Haddad, et al.
Published: (2022-02-01)

In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity
by: Kazuhiro J. Fujimoto, et al.
Published: (2022-02-01)

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population levelResearch in context
by: Anouschka Akerman, et al.
Published: (2023-04-01)

Cigarette Smoke Stimulates SARS-CoV-2 Internalization by Activating AhR and Increasing ACE2 Expression in Human Gingival Epithelial Cells
by: Cassio Luiz Coutinho Almeida-da-Silva, et al.
Published: (2021-07-01)

Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics
by: Hyung Muk Choi, et al.
Published: (2021-02-01)

SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
by: Ishita Gupta, et al.
Published: (2020-08-01)

Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review
by: Aneta Aleksova, et al.
Published: (2021-04-01)

ACE-2, TMPRSS2, and Neuropilin-1 Receptor Expression on Human Brain Astrocytes and Pericytes and SARS-CoV-2 Infection Kinetics
by: Johid Reza Malik, et al.
Published: (2023-05-01)

Is There a Link between Bisphenol A (BPA), a Key Endocrine Disruptor, and the Risk for SARS-CoV-2 Infection and Severe COVID-19?
by: Aeman Zahra, et al.
Published: (2020-10-01)

Nutrients, herbal bioactive derivatives and commensal microbiota as tools to lower the risk of SARS-CoV-2 infection
by: Arianna Romani, et al.
Published: (2023-06-01)

Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review
by: Weihang He, et al.
Published: (2022-06-01)

Identification of Novel Hypothalamic MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating ACE2 and TMPRSS2 Expression: An In Silico Analysis
by: Debasmita Mukhopadhyay, et al.
Published: (2020-09-01)

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells
by: Rolando Cannalire, et al.
Published: (2020-08-01)

Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin
by: Anna Ohradanova-Repic, et al.
Published: (2022-08-01)

SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells
by: Yu-Qiang Yu, et al.
Published: (2022-04-01)

Genetic Variants within SARS-CoV-2 Human Receptor Genes May Contribute to Variable Disease Outcomes in Different Ethnicities
by: Theolan Adimulam, et al.
Published: (2023-05-01)

Ocular Symptoms Associated with COVID-19 Are Correlated with the Expression Profile of Mouse SARS-CoV-2 Binding Sites
by: Julien Brechbühl, et al.
Published: (2023-01-01)

Identification of human genetic variants modulating the course of COVID-19 infection with importance in other viral infections
by: Lana Salihefendić, et al.
Published: (2023-08-01)

Development and evaluation of a novel chromium III-based compound for potential inhibition of emerging SARS-CoV-2 variants
by: Yu-Jung Lin, et al.
Published: (2023-09-01)

Potential Treatment Approaches to SARS-CoV-2 and Evaluation of Drug Carrier Systems in Treatment
by: Sema ARISOY, et al.
Published: (2020-12-01)